Screening for type 2 diabetes mellitus in overweight and obese subjects made easy by the FINDRISC score

Autor: Meijnikman, A.S., De Block, C.E.M., Verrijken, A., Mertens, I., Corthouts, B., Van Gaal, L.F.

Publikováno v: In Journal of Diabetes and Its Complications August 2016 30(6):1043-1049

Médicaments de l’obésité et risque cardiovasculaire

Autor: Scheen, A.J., Van Gaal, L.F.

Publikováno v: In Médecine des maladies métaboliques February 2012 6(1):31-37

Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolaemics

Autor: Van Gaal, L.F., Peeters, A.V., De Block, C.E.M., de Leeuw, I.H., Thiart, R., Kotze, M.J.

Publikováno v: In Molecular and Cellular Probes December 2001 15(6):329-336

Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk factors in subjects with type 2 diabetes

Autor: Diamant, M., van Gaal, L.F., Stranks, S.N., Northrup, J., Cao, D., Taylor, K., Trautmann, M.

Publikováno v: Diabetologia, 53. Springer Verlag
Diamant, M, van Gaal, L F, Stranks, S N, Northrup, J, Cao, D, Taylor, K & Trautmann, M 2010, ' Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk factors in subjects with type 2 diabetes ', Diabetologia, vol. 53, pp. 863 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::031d2a1717d47c84693dec0863ccea50
https://research.vumc.nl/en/publications/59064c6d-8613-4433-add3-1b1ec85267dd

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance

Autor: Hansen, D.L., Astrup, A.V., Toubro, S., Finer, N., Kopelman, P., Hilsted, J., Rossner, S., Saris, W.H.M., van Gaal, L.F., James, W.P.T., Goulder, M.

Publikováno v: International Journal of Obesity, 25, 496-501. Nature Publishing Group

Int J Obes Relat Metab Disord 2001 Apr;25(4):496-501 Related Articles, Books, LinkOut Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::5cb4d2853fc268ddc6a04a70eabc86c1
https://cris.maastrichtuniversity.nl/en/publications/92d180a1-4fda-453a-af02-654185d1f3c6